A preliminary study on the diversity of butyrate-producing bacteria in response to the treatment of depression with Xiaoyaosan

Xiong, Lin-Lin; Mao, Meng-Lin; Shu, Qinglong

doi:10.1111/lam.13737

Cited by 7 publications

(3 citation statements)

References 39 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study revealed that 125 and 87 OTUs were uniquely present in non-remission and remission groups, respectively ( Duan et al, 2021 ). Clostridiales was strongly negatively correlated with the severity of depression ( Liskiewicz et al, 2021 ; Xiong et al, 2022 ; Wang et al, 2023 ). An increase in the abundance of the order Clostridiales was found in the remission group after 6 months of escitalopram treatment ( Bharwani et al, 2020 ).…”

Section: Baseline Changes In Gut Microbiota During Different Response...mentioning

confidence: 99%

“…In addition, enrichment of Agathobacter ( Lee et al, 2022 ), Coprococcus ( Valles-Colomer et al, 2019 ; Gao et al, 2023 ), Roseburia ( Zhou et al, 2023 ), and Eubacterium ( Xiong et al, 2022 ; Wang et al, 2023 ) was associated with the treatment outcome of remission. The increased relative abundances of the family Christensenellaceae ( Dong et al, 2022 ) and decreased relative abundances of the families Ruminococcaceae, Lactobacillaceae, and Peptostreptococcaceae and the genera Coprococcus ( Sanada et al, 2020 ), Oscillibacter ( Xiong et al, 2022 ), Tyzzerella , and Butyricicoccus ( Shen et al, 2023 ) were related to non-remission ( Fontana et al, 2020 ; Duan et al, 2021 ).…”

Section: Baseline Changes In Gut Microbiota During Different Response...mentioning

confidence: 99%

See 1 more Smart Citation

Baseline gut microbiota profiles affect treatment response in patients with depression

Xie,

Zhu,

Yuan

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

The role of the gut microbiota in the pathophysiology of depression has been explored in numerous studies, which have confirmed that the baseline gut microbial profiles of patients with depression differ from those of healthy individuals. The gut microbiome affects metabolic activity in the immune and central nervous systems and regulates intestinal ecology through the neuroendocrine system. Additionally, baseline changes in the gut microbiota differed among patients with depression who demonstrated varying treatment response. Currently, probiotics are an emerging treatment for depression; however, the efficacy of modulating the gut microbiota in the treatment of depression remains uncertain. Additionally, the mechanisms by which changes in the gut microbiota affect treatment response in patients with depression remain unclear. In this review, we aimed to summarize the differences in the baseline gut microbiota between the remission and non-remission groups after antidepressant therapy. Additionally, we summarized the possible mechanisms that may contribute to antidepressant resistance through the effects of the gut microbiome on the immune and nervous systems, various enzymes, bioaccumulation, and blood–brain barrier, and provide a basis for treating depression by targeting the gut microbiota.

show abstract

Section: Baseline Changes In Gut Microbiota During Different Response...mentioning

confidence: 99%

Section: Baseline Changes In Gut Microbiota During Different Response...mentioning

confidence: 99%

Baseline gut microbiota profiles affect treatment response in patients with depression

Xie,

Zhu,

Yuan

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Results of their study supported that ZZCD is capable of inducing an antidepressant effect via re-shaping gut microbiota and facilitating butyrate production, which in turn inhibited the release of pro-inflammatory cytokines and modulated BDNF and neurotransmitters along the gut-brain axis. Another study has shown that Xiaoyaosan also increases intestinal butyrate-producing bacterial diversity and subsequently improves depressive-disorders-like behaviors in rats [144]. Xiong et al also applied Xiaoyaosan polysaccharide for alleviating CUMS-induced depressivedisorders-like behaviors in rats.…”

Section: Polyphenols and Herbal Medicine As Prebiotics For Depressive...mentioning

confidence: 99%

Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies

Nohesara,

Abdolmaleky,

Zhou

et al. 2023

Genes

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a complex disorder and a leading cause of disability in 280 million people worldwide. Many environmental factors, such as microbes, drugs, and diet, are involved in the pathogenesis of depressive disorders. However, the underlying mechanisms of depression are complex and include the interaction of genetics with epigenetics and the host immune system. Modifications of the gut microbiome and its metabolites influence stress-related responses and social behavior in patients with depressive disorders by modulating the maturation of immune cells and neurogenesis in the brain mediated by epigenetic modifications. Here, we discuss the potential roles of a leaky gut in the development of depressive disorders via changes in gut microbiota-derived metabolites with epigenetic effects. Next, we will deliberate how altering the gut microbiome composition contributes to the development of depressive disorders via epigenetic alterations. In particular, we focus on how microbiota-derived metabolites such as butyrate as an epigenetic modifier, probiotics, maternal diet, polyphenols, drugs (e.g., antipsychotics, antidepressants, and antibiotics), and fecal microbiota transplantation could positively alleviate depressive-like behaviors by modulating the epigenetic landscape. Finally, we will discuss challenges associated with recent therapeutic approaches for depressive disorders via microbiome-related epigenetic shifts, as well as opportunities to tackle such problems.

show abstract

Butyrate’s (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer

Karim,

Iqbal,

Mohammad

et al. 2024

Arch Microbiol

View full text Add to dashboard Cite

A preliminary study on the diversity of butyrate-producing bacteria in response to the treatment of depression with Xiaoyaosan

Cited by 7 publications

References 39 publications

Baseline gut microbiota profiles affect treatment response in patients with depression

Baseline gut microbiota profiles affect treatment response in patients with depression

Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies

Butyrate’s (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer

Contact Info

Product

Resources

About